Salivary Duct Carcinoma
Associated Genetic Biomarkers
NCI Definition: An aggressive, high grade adenocarcinoma that arises from the salivary glands. It usually affects elderly males and presents as a rapidly enlarging mass. It metastasizes to regional lymph nodes and distant anatomic sites. 
Salivary duct carcinomas most frequently harbor alterations in TP53, ERBB2, PIK3CA, NF1, and HRAS .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in salivary duct carcinoma .
There are 2 clinical trials for salivary duct carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain salivary duct carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
ERBB2 is the most frequent gene inclusion criterion for salivary duct carcinoma clinical trials .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most common interventions in salivary duct carcinoma clinical trials.
Significant Genes in Salivary Duct Carcinoma
ERBB2 is mutated in 27.16% of salivary duct carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary duct carcinoma trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.